Novozymes acquires Iogen Bio-Products, industrial enzyme business of Ottawa-based Iogen Corporation for CAD 67.5 million (approximately DKK 370 million) and potential earn-out payments of up to CAD 12.5 million (approximately DKK 70 million). The deal provides Novozymes with all commercial rights to Iogen Bio-Products' existing product portfolio, pipeline, facilities and know-how. Novozymes acquires all of Iogen's industrial enzyme business. The acquisition does not include the purchase of assets that relate to Iogen's bioenergy process technologies.

Iogen Bio-Products, which entered the industrial enzyme industry in 1991, produces and sells enzymes for the pulp & paper, textile, grain-processing and animal feed industries. The company has close to 70 employees and sells more than 20 products globally.

Financial impact

The acquisition is expected to have a positive impact on Novozymes' sales growth in 2013 of around 0.5 percentage point depending on when the acquisition is closed. The acquisition is expected to have a slightly negative impact on EBIT and EBIT margin in 2013, but outlook for EBIT growth and EBIT margin remains unchanged. The outlook for ROIC for 2013 is being changed from ~20% to 19-20% as a result of the additional capital invested. Novozymes' outlook for free cash flow excludes acquisitions and remains unchanged for 2013. Outlook assumes rates for the company^'s key currencies remain at the closing rates on January 18 for the rest of 2013.

Closing of the acquisition is anticipated late February 2013, awaiting finalization of corporate formalities.